[New aspects in the treatment of neovascular age-related macular degeneration: the criteria of re-treatment with the anti-VEGF therapy.].
Der Ophthalmologe (Impact Factor: 0.53). 01/2011; 108(1):85-90. DOI: 10.1007/s00347-010-2326-1
- Der Ophthalmologe 05/2013; · 0.53 Impact Factor
- Acta ophthalmologica 11/2012; · 2.44 Impact Factor
- Journal of Ophthalmology 01/2014; 2014:346360. · 1.37 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.